Candel Therapeutics (CADL) announced it will deliver three presentations at the Society for Immunotherapy of Cancer, SITC, 40th Anniversary Annual Meeting, taking place November 5-9, 2025, in National Harbor, Maryland. “Candel’s presentations at SITC 2025 exemplify our innovative approach to the discovery and development of novel immunotherapies,” said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel Therapeutics. “By leveraging next-generation research tools we are working to generate deep biological insights that inform every stage of drug development, from bench to bedside and back. This iterative process allows us to refine how we develop a novel class of immunotherapies that have the potential to improve clinical outcome in patients with difficult-to-treat solid tumors.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Candel initiated with an Overweight at Stephens on differentiated pipeline
- Candel Therapeutics initiated with an Overweight at Stephens
- Positive Buy Rating for Candel Therapeutics Driven by Promising Phase 3 Results of CAN-2409 and Strong Regulatory Prospects
- Candel Therapeutics initiated with an Outperform at LifeSci Capital
- Candel Therapeutics appoints Pulendran to Candel’s RAB